Support requiring pharmaceutical companies to charge more reasonable prices for drugs used by low-income seniors and people with disabilities under Medicare Part D.

I support the Medicare Drug Savings Act, which would require pharmaceutical companies to charge more reasonable prices for drugs used by low­-income seniors and people with disabilities, a common-sense change to level the playing field for Medicare Part D and save taxpayers money.

Schatz commits to supporting Medicare Part D drug pricing reforms for low-income seniors and people with disabilities.

Candidate Q&A — U.S. Senate: Brian Schatz - Honolulu Civil Beat
primary · interview · model gpt-5.5

Co-sponsoring legislation to reduce prescription drug costs for Medicare, and fighting to require pharmaceutical companies to reduce drug prices for low-income seniors and people with disabilities.

The campaign says Schatz supports legislation to lower Medicare prescription drug costs and require drugmakers to reduce prices for low-income seniors and people with disabilities.

accomplishments.pdf
campaign · campaign_site · model gpt-5.5

Schatz joined the Medicare Drug Savings Act, which would require rebates for drugs used by dual eligibles and other low-income-subsidy Medicare Part D enrollees.

Shows Schatz clearly supported the specific targeted Part D rebate policy for low-income seniors and people with disabilities.

partial same_term A for effort

Schatz Joins Rockefeller and 17 Other Senators to Introduce Legislation That Protects Seniors and Reduces Deficit By $141.2 Billion
secondary · model gpt-5.5 · confidence 93%

Congress.gov lists S.740 as introduced and referred to Senate Finance. CRS says it required manufacturer rebates for rebate-eligible low-income Part D individuals.

The direct bill matching the promise did not become law, but Schatz-backed legislation existed.

never unknown A for effort

S.740 - Medicare Drug Savings Act of 2013
secondary · model gpt-5.5 · confidence 92%

On passage of H.R. 5376 as amended, the bill passed 50-50 with the Vice President voting yea; Schatz (D-HI) voted yea.

Schatz voted for the Inflation Reduction Act, which later became the vehicle for Medicare Part D negotiation and manufacturer rebate provisions.

partial later_term A for effort

U.S. Senate Roll Call Vote 117th Congress, Vote 325
secondary · model gpt-5.5 · confidence 95%

CMS says the Inflation Reduction Act gives Medicare direct negotiation authority; negotiated maximum fair prices for 10 Part D drugs took effect January 1, 2026.

A broader Part D price-reduction mechanism was implemented, though not limited to low-income seniors or disabled beneficiaries.

partial later_term

Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026
secondary · model gpt-5.5 · confidence 94%

CMS says it assessed inflation rebates to manufacturers that raised prices of certain Medicare Part D drugs faster than inflation, with first invoices covering periods beginning October 1, 2022 and October 1, 2023.

Manufacturer rebate enforcement under Part D was implemented, but it is an inflation-rebate program rather than the exact low-income-subsidy rebate proposal.

partial later_term

Medicare Inflation Rebate Program
secondary · model gpt-5.5 · confidence 93%